---
title: "Bleeding Risk in Atrial Fibrillation: Apixaban or Rivaroxaban With Diltiazem vs Metoprolol"
id: "annals-of-internal-medicine-87-the-risk-for-bleeding-in-patients-with-atrial-fibrillation-from-concomitant-use-of-apixaban-or-rivaroxaban-with-diltiazem-compared-with-metoprolol"
canonical_url: "https://medichelpline.com/clinical-feed/annals-of-internal-medicine-87-the-risk-for-bleeding-in-patients-with-atrial-fibrillation-from-concomitant-use-of-apixaban-or-rivaroxaban-with-diltiazem-compared-with-metoprolol"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "Annals of Internal Medicine (ACP)"
source_url: "https://www.acpjournals.org/doi/abs/10.7326/ANNALS-25-01408?af=R"
published_at: "2026-02-24T08:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Bleeding Risk in Atrial Fibrillation: Apixaban or Rivaroxaban With Diltiazem vs Metoprolol
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/annals-of-internal-medicine-87-the-risk-for-bleeding-in-patients-with-atrial-fibrillation-from-concomitant-use-of-apixaban-or-rivaroxaban-with-diltiazem-compared-with-metoprolol
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** Annals of Internal Medicine (ACP)
- **Source URL:** [Original Journal Publication](https://www.acpjournals.org/doi/abs/10.7326/ANNALS-25-01408?af=R)
- **Published At:** 2026-02-24T08:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Annals of Internal Medicine (ACP) published a clinical update in Research Highlights on 24 Feb 2026. The item focuses on The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol. Review the original article for the full source wording and details.
## Clinical Analysis & Structured Key Points
Annals of Internal Medicine (ACP) published a clinical update in Research Highlights on 24 Feb 2026. The item focuses on The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol. Review the original article for the full source wording and details.
## Related Clinical Research

- [Clinical Outcomes of Switching vs. Continuing Direct Oral Anticoagulants (DOACs) After Ischemic Stroke in Patients with Atrial Fibrillation in the US](https://medichelpline.com/clinical-feed/medrxiv-7-clinical-outcomes-of-switching-vs-continuing-direct-oral-anticoagulants-doacs.md)
- [New oral anticoagulants linked to slower cognitive decline in Alzheimer’s patients with AFib](https://medichelpline.com/clinical-feed/medical-news-today-0-new-oral-anticoagulants-may-help-slow-cognitive-decline-in-alzheimer-s-disease.md)
- [NOAC monotherapy vs NOAC+clopidogrel by age in AF patients with drug-eluting stents](https://medichelpline.com/clinical-feed/pubmed-42546025.md) (DOI: 10.1093/ageing/afag224)
- [Goodbye “Massive” and “Submassive”](https://medichelpline.com/clinical-feed/litfl-5-goodbye-massive-and-submassive-.md)
- [Abelacimab Versus Rivaroxaban in Older Adults With Atrial Fibrillation](https://medichelpline.com/clinical-feed/jama-cardiology-6-abelacimab-vs-rivaroxaban-in-older-individuals-with-af.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.